- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Antiplatelet Therapies for Atherothrombotic Diseases
Authors
Keywords
-
Journal
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Volume 39, Issue 4, Pages 546-557
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2019-02-14
DOI
10.1161/atvbaha.118.310955
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
- (2018) Larisa H. Cavallari et al. JACC-Cardiovascular Interventions
- Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers
- (2018) Sara Ariotti et al. JACC-Cardiovascular Interventions
- Current and future antiplatelet therapies: emphasis on preserving haemostasis
- (2018) James D. McFadyen et al. Nature Reviews Cardiology
- Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
- (2018) S. Claiborne Johnston et al. NEW ENGLAND JOURNAL OF MEDICINE
- The intersection of protein disulfide isomerase and cancer associated thrombosis
- (2018) Jack D. Stopa et al. THROMBOSIS RESEARCH
- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
- (2018) J Michael Gaziano et al. LANCET
- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
- (2018) John J. McNeil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- Cangrelor Use in Cardiogenic Shock
- (2017) Muthiah Vaduganathan et al. JACC-Cardiovascular Interventions
- Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention
- (2017) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary
- (2017) Marie D. Gerhard-Herman et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks
- (2017) Kristell Lebozec et al. mAbs
- Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
- (2017) William R. Hiatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synergistic effect of peptide inhibitors derived from the extracellular and intracellular domain of αIIb subunit of integrin αIIbβ3 on platelet activation and aggregation
- (2017) Alexia V. Gkourogianni et al. PLATELETS
- Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation
- (2017) Ann-Katrin Mojica Muñoz et al. THROMBOSIS AND HAEMOSTASIS
- HPW-RX40 prevents human platelet activation by attenuating cell surface protein disulfide isomerases
- (2017) Po-Hsiung Kung et al. Redox Biology
- PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation
- (2017) Simon J. Wilson et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study
- (2016) Usman Baber et al. AMERICAN HEART JOURNAL
- Simultaneous Platelet P2Y12and P2Y1ADP Receptor Blockade
- (2016) Muthiah Vaduganathan et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Synergistic Inhibition of Both P2Y1and P2Y12Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated ThrombosisSignificance
- (2016) Thomas Gremmel et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple DefinitionsClinical Perspective
- (2016) Matthew A. Cavender et al. CIRCULATION
- Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease
- (2016) William Herrington et al. CIRCULATION RESEARCH
- Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention
- (2016) Neal N. Sawlani et al. Circulation-Cardiovascular Interventions
- International patterns of dual antiplatelet therapy duration after acute coronary syndromes
- (2016) Héctor Bueno et al. HEART
- Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54
- (2016) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
- (2016) Marc P. Bonaca et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
- (2016) Glenn N. Levine et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack
- (2016) S. Claiborne Johnston et al. NEW ENGLAND JOURNAL OF MEDICINE
- Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar
- (2015) O. Aisiku et al. BLOOD
- A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury
- (2015) Ting-Ting Li et al. BRITISH JOURNAL OF PHARMACOLOGY
- Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man
- (2015) S. Nylander et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys
- (2015) Pancras C. Wong et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
- (2015) Marc P. Bonaca et al. NEW ENGLAND JOURNAL OF MEDICINE
- RUC-4
- (2014) Jihong Li et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Rising Like the Phoenix?
- (2014) Edward F. Plow et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Platelet PI3K and GSK3 regulate thrombus stability at a high shear rate
- (2014) P.-A. Laurent et al. BLOOD
- Discovery of 4-Aryl-7-Hydroxyindoline-Based P2Y1 Antagonists as Novel Antiplatelet Agents
- (2014) Wu Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
- (2014) Walter N. Kernan et al. STROKE
- SAR216471, an alternative to the use of currently available P2Y12 receptor inhibitors?
- (2014) N. Delesque-Touchard et al. THROMBOSIS RESEARCH
- Vorapaxar in Patients With Peripheral Artery Disease
- (2013) Marc P. Bonaca et al. CIRCULATION
- Lead Optimization of Ethyl 6-Aminonicotinate Acyl Sulfonamides as Antagonists of the P2Y12 Receptor. Separation of the Antithrombotic Effect and Bleeding for Candidate Drug AZD1283
- (2013) Peter Bach et al. JOURNAL OF MEDICINAL CHEMISTRY
- Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial
- (2013) Stephen D Wiviott et al. LANCET
- Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data
- (2013) Philippe Gabriel Steg et al. LANCET
- Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
- (2013) Roxana Mehran et al. LANCET
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
- (2013) Yongjun Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events
- (2013) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- The GPVI – Fc Fusion Protein Revacept Reduces Thrombus Formation and Improves Vascular Dysfunction in Atherosclerosis without Any Impact on Bleeding Times
- (2013) Martin Ungerer et al. PLoS One
- Efficacy and Safety of Vorapaxar in Patients With Prior Ischemic Stroke
- (2013) David A. Morrow et al. STROKE
- Pharmacokinetic and Pharmacodynamic Effects of Elinogrel
- (2012) Dominick J. Angiolillo et al. Circulation-Cardiovascular Interventions
- The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study
- (2012) Deepak L. Bhatt et al. EUROPEAN HEART JOURNAL
- Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor
- (2012) S. NYLANDER et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
- (2012) Matthew T. Roe et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vorapaxar in the Secondary Prevention of Atherothrombotic Events
- (2012) David A. Morrow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platelet GPVI: a target for antithrombotic therapy?!
- (2012) Sebastian Dütting et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- von Willebrand Factor Inhibition Improves Endothelial Function in Patients with Stable Angina
- (2012) Olivier Muller et al. Journal of Cardiovascular Translational Research
- Antiplatelet and antithrombotic effect of F 16618, a new thrombin proteinase-activated receptor-1 (PAR1) antagonist
- (2011) M Dumas et al. BRITISH JOURNAL OF PHARMACOLOGY
- Novel Antiplatelet Drug Revacept (Dimeric Glycoprotein VI-Fc) Specifically and Efficiently Inhibited Collagen-Induced Platelet Aggregation Without Affecting General Hemostasis in Humans
- (2011) Martin Ungerer et al. CIRCULATION
- Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease
- (2011) Stephen D. Wiviott et al. CIRCULATION
- Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes
- (2011) Michelle L. O'Donoghue et al. CIRCULATION
- Genetic Polymorphisms and the Impact of a Higher Clopidogrel Dose Regimen on Active Metabolite Exposure and Antiplatelet Response in Healthy Subjects
- (2011) T Simon et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The von Willebrand Inhibitor ARC1779 Reduces Cerebral Embolization After Carotid Endarterectomy
- (2011) Hugh S. Markus et al. STROKE
- Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
- (2010) S. Goto et al. EUROPEAN HEART JOURNAL
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment
- (2010) Guillaume Paré et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with peripheral arterial disease in the CHARISMA trial
- (2009) P. P. Cacoub et al. EUROPEAN HEART JOURNAL
- Design and humanization of a murine scFv that blocks human platelet glycoprotein VIin vitro
- (2009) Julien Muzard et al. FEBS Journal
- Intravenous Platelet Blockade with Cangrelor during PCI
- (2009) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
- (2009) Lars Wallentin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platelet Inhibition with Cangrelor in Patients Undergoing PCI
- (2009) Robert A. Harrington et al. NEW ENGLAND JOURNAL OF MEDICINE
- A small-molecule inhibitor of integrin α2β1 introduces a new strategy for antithrombotic therapy
- (2009) Jarmo Käpylä et al. THROMBOSIS AND HAEMOSTASIS
- Advantages of a selective β-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat
- (2008) Sharelle A. Sturgeon et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Ex vivo inhibition of thrombus formation by an anti-glycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression
- (2008) P. OHLMANN et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More